Drugs / Tobradex
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TOBRADEX | — | 1988-08-18 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00404937 | Dec 2006 | — | Alcon Research | Withdrawn | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00695435 Comparator | Jun 2008 | dry eye syndrome | Alcon Research | Completed | No outcome recorded |
| — | NCT03105466 Background | Feb 2016 → Feb 2020 | — | Zhongshan Ophthalmic Center, Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02558218 Comparator | Jan → May 2015 | cataract | Democritus University of Thrace | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOBRADEX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00695435 ↗ |
| Route | Topical | “0.3% Tobradex eyedrops, four times-one times a day for one year” NCT03105466 ↗ |